Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Decreases By 41.1%

Artelo Biosciences, Inc. (NASDAQ:ARTL) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 8,600 shares, a drop of 41.1% from the January 15th total of 14,600 shares. Based on an average trading volume of 35,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the company’s stock are short sold.

Artelo Biosciences Trading Down 14.4 %

NASDAQ ARTL opened at $1.19 on Friday. Artelo Biosciences has a fifty-two week low of $0.91 and a fifty-two week high of $1.73. The stock has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $1.17.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. On average, research analysts anticipate that Artelo Biosciences will post -2.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a research report on Wednesday, December 25th. D. Boral Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Artelo Biosciences in a research note on Tuesday, January 14th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a research note on Monday, December 9th.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.